Letter ·
NAMD Urges Congress to Address Break Through Drugs
In October 2014, NAMD called on Congress to provide new tools for states to manage prescription drug costs.
In October 2014, NAMD called on Congress to provide new tools for states to manage the exorbitant costs of specialty drugs entering the market. This letter was triggered by the introduction of curative hepatitis C therapies, which illustrate fundamental challenges in Medicaid drug coverage and reimbursement that need statutory solutions.
Related resources
NAMD Comments on Medicare’s Proposed Coverage Determination for Alzheimer’s Drug
NAMD Urges CMS to Mitigate State Costs on Controversial Alzheimer’s Drug
Stay Informed
Drop us your email and we’ll keep you up-to-date on Medicaid issues.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.